You just read:

ORYZON Announces First Subject Dosed in Phase I Healthy Volunteer Study Evaluating Oral Epigenetic drug ORY-2001 for Alzheimer's Disease

News provided by

Oryzon Genomics

04 Apr, 2016, 08:00 ET